[Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].

MLA

Zechmann, Stefan. “[Empagliflozin: An Oral Antidiabetic with Documented Positive Effect on Cardiac Mortality].” Praxis, vol. 105, no. 6, Mar. 2016, pp. 349–50. EBSCOhost, https://doi.org/10.1024/1661-8157/a002288.

APA

Zechmann, S. (2016). [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality]. Praxis, 105(6), 349–350. https://doi.org/10.1024/1661-8157/a002288

Chicago

Zechmann, Stefan. 2016. “[Empagliflozin: An Oral Antidiabetic with Documented Positive Effect on Cardiac Mortality].” Praxis 105 (6): 349–50. doi:10.1024/1661-8157/a002288.